PUBLIC DEMONSTRATION · 26 AUGUST 2026
PRT13722
Selective oral KAT6A degradation in HR-positive / HER2-negative advanced breast cancer.
The assessment supports continued diligence and a bounded evidence-generating increment. It does not support a major commitment priced as though clinical differentiation has been established.
START HERE · QUICK OVERVIEW
The sample brief
A five-page overview of the full demonstration assessment, designed for a quicker read. See the decision, key evidence and uncertainties before exploring the detailed science.
5 pages · A shortened companion, not a substitute for the full evidence and source record
Go deeper into the science
The full demonstration assessment explains the scientific evidence and reasoning behind the HOLD decision, including the nine-stage analysis, critical risks, decisive experiments and source record.
Download full demonstration assessment (PDF)
21 pages · Assessment and research cutoff: 26 August 2026
What drives the decision
01 — Translation remains unproven
The completed record contains no public human PRT13722 exposure, tumor degradation, safety or efficacy data.
02 — Selectivity must create a useful therapeutic window
KAT6B sparing alone does not establish an acceptable hematologic window or clinical advantage.
03 — Exact-candidate evidence matters
Several key PK and tumor-PD datasets concern PRT13722*, requiring an explicit bridge to the exact candidate.
What would change the decision
Practical human exposure, sustained tumor KAT6A degradation, preserved selectivity, an acceptable hematologic window, and initial PD-linked activity. The report sets out the evidence gates and prioritized experiments.
Inside the report
Executive assessment, nine-stage analysis, critical risk register, decisive experiment plan, capital gate and source record.
Prepared solely as a demonstration of Gateway Lantern’s methodology. PRT13722, its sponsor and affiliated parties were not clients, did not commission the work and supplied no confidential information. Findings reflect the report dated 26 August 2026 and may change with new evidence. This is not investment advice, a legal opinion or independent experimental validation.